アフェレーシスの世界市場予測（～2021年）：血漿分離器、血漿成分分離器、血液灌流、消耗品...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY DATA 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY DATA 24
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 25
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.4 MARKET SHARE ESTIMATION 28
2.4.1 ASSUMPTIONS FOR THE STUDY 28

3 EXECUTIVE SUMMARY 29

4 PREMIUM INSIGHTS 36
4.1 APHERESIS: MARKET OVERVIEW 36
4.2 ASIA-PACIFIC: APHERESIS MARKET, BY APPLICATION 37
4.3 GEOGRAPHIC SNAPSHOT OF THE APHERESIS MARKET 38
4.4 GEOGRAPHIC MIX: APHERESIS MARKET 39
4.5 APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
5.2.1 MARKET DRIVERS 42
5.2.1.1 Rising prevalence of diseases and growing number of trauma and injury cases 42
5.2.1.2 Increasing demand for source plasma from biopharmaceutical companies 44
5.2.1.3 Rising demand for blood components and growing concerns regarding blood safety 45
5.2.1.4 Increase in the number of complex surgical procedures 45
5.2.1.5 Favorable reimbursement policies for apheresis procedures 46
5.2.2 MARKET RESTRAINTS 46
5.2.2.1 Lack of awareness about apheresis procedures 47
5.2.2.2 High cost of apheresis devices and procedures 47
5.2.2.3 Scarcity of qualified donors 47
5.2.3 MARKET OPPORTUNITIES 48
5.2.3.1 Extending the reach of apheresis in the untapped pediatric segment 48
5.2.3.2 Emerging economies with increasing investments from government bodies and leading players 48
5.2.4 MARKET CHALLENGES 49
5.2.4.1 Recruitment of voluntary non-remunerated donors 49
5.2.4.2 Blood transfusion safety in developing countries 50

6 INDUSTRY INSIGHTS 51
6.1 INTRODUCTION 51
6.2 INDUSTRY TRENDS 51
6.2.1 NEW INDICATIONS FOR PLASMA PRODUCTS 51
6.2.2 GROWING NUMBER OF AGREEMENTS AND PARTNERSHIPS 51
6.3 PORTER’S FIVE FORCE ANALYSIS 53
6.3.1 THREAT OF NEW ENTRANTS 53
6.3.2 THREAT OF SUBSTITUTES 54
6.3.3 BARGAINING POWER OF SUPPLIERS 54
6.3.4 BARGAINING POWER OF BUYERS 54
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 55
6.4 VENDOR BENCHMARKING 55
6.4.1 PRODUCT PORTFOLIO ANALYSIS: APHERESIS MARKET 55
6.5 REGULATORY ANALYSIS 57
6.5.1 NORTH AMERICA 57
6.5.1.1 U.S. 57
6.5.1.2 Canada 58
6.5.2 EUROPE 58
6.5.3 ASIA-PACIFIC 59
6.5.3.1 Japan 59
6.5.3.2 China 59
6.5.3.3 India 60

7 GLOBAL APHERESIS MARKET, BY PROCEDURE 61
7.1 INTRODUCTION 62
7.2 AUTOMATED/APHERESIS BLOOD COLLECTION (DONOR APHERESIS) 63
7.3 THERAPEUTIC APHERESIS 64
7.3.1 THERAPEUTIC APHERESIS MARKET, BY DISEASE 65
7.3.1.1 Neurological Disorders 67
7.3.1.2 Blood Disorders 69
7.3.1.3 Cardiovascular Disorders 70
7.3.1.4 Renal Disorders 71
7.3.1.5 Autoimmune Disorders 72
7.3.1.6 Metabolic Disorders 73
7.3.1.7 Other Disorders 75
7.3.2 THERAPEUTIC APHERESIS MARKET, BY PROCEDURE 76
7.3.2.1 Therapeutic Plasma Exchange (TPE) 76
7.3.2.2 Therapeutic Cytapheresis 78
7.3.2.2.1 Therapeutic Erythrocytapheresis 79
7.3.2.2.2 Therapeutic Plateletphersis 80
7.3.2.2.3 Leukapheresis 81
7.3.2.3 Photopheresis 83
7.3.2.4 Extracorporeal Immunoadsorption (ECI) 84

8 GLOBAL APHERESIS MARKET, BY PRODUCT 85
8.1 INTRODUCTION 86
8.2 APHERESIS DEVICES 87
8.2.1 PLASMA SEPARATORS 90
8.2.2 PLASMA COMPONENT SEPARATORS 91
8.2.3 IMMUNOADSORPTION COLUMNS 92
8.2.4 PLASMA PERFUSION COLUMNS 93
8.2.5 HEMOPERFUSION COLUMNS 94
8.3 APHERESIS DISPOSABLES 95

9 GLOBAL APHERESIS MARKET, BY TECHNOLOGY 97
9.1 INTRODUCTION 98
9.2 CENTRIFUGATION 99
9.2.1 INTERMITTENT FLOW 101
9.2.2 CONTINUOUS FLOW 102
9.3 MEMBRANE SEPARATION 103
 

10 GLOBAL APHERESIS MARKET, BY APPLICATION 105
10.1 INTRODUCTION 106
10.2 PLASMAPHERESIS 107
10.3 PLATELETPHERESIS 108
10.4 ERYTHROCYTAPHERESIS 109
10.5 LEUKAPHERESIS 110
10.6 OTHER APPLICATIONS 111

11 APHERESIS MARKET, BY REGION 113
11.1 INTRODUCTION 114
11.2 NORTH AMERICA 116
11.2.1 U.S. 120
11.2.2 CANADA 122
11.3 EUROPE 124
11.3.1 GERMANY 128
11.3.2 FRANCE 130
11.3.3 U.K. 132
11.3.4 ITALY 134
11.3.5 SPAIN 136
11.3.6 REST OF EUROPE (ROE) 138
11.4 ASIA-PACIFIC (APAC) 140
11.4.1 JAPAN 144
11.4.2 CHINA 146
11.4.3 INDIA 148
11.4.4 REST OF ASIA-PACIFIC (ROAPAC) 150
11.5 LATIN AMERICA 152
11.5.1 BRAZIL 155
11.5.2 MEXICO 157
11.5.3 REST OF LATIN AMERICA (ROLA) 159
11.6 MIDDLE EAST AND AFRICA 161

12 COMPETITIVE LANDSCAPE 164
12.1 OVERVIEW 164
12.2 MARKET SHARE ANALYSIS 165
12.3 COMPETITIVE SITUATION AND TRENDS 166
12.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 166
12.5 MERGERS AND ACQUISITIONS 167
12.6 EXPANSIONS 168
12.7 PRODUCT LAUNCHES 168
12.8 OTHER STRATEGIES 169
 

13 COMPANY PROFILES 170
(Overview, Products & Services, Strategies & Insights, Developments and MnM View)*
13.1 INTRODUCTION 170
13.2 CERUS CORPORATION 171
13.3 FRESENIUS SE & CO. KGAA 175
13.4 ASAHI KASEI MEDICAL CO., LTD. (A SUBSIDIARY OF ASAHI KASEI CORPORATION) 178
13.5 HAEMONETICS CORPORATION 180
13.6 TERUMO BCT, INC. 183
13.7 HEMACARE CORPORATION 186
13.8 B. BRAUN MELSUNGEN AG 188
13.9 KANEKA CORPORATION 190
13.10 KAWASUMI LABORATORIES INC. 192
13.11 NIKKISO CO., LTD. 194
*Details on Overview, Products & Services, Strategies & Insights, Developments and MnM View might not be captured in case of unlisted companies.

14 APPENDIX 196
14.1 INSIGHTS OF INDUSTRY EXPERTS 196
14.2 DISCUSSION GUIDE 197
14.3 OTHER DEVELOPMENTS 202
14.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 206
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 208
14.6 AVAILABLE CUSTOMIZATIONS 210
14.7 RELATED REPORTS 211
14.8 AUTHOR DETAILS 212